title: [Side effect management of tyrosine kinase inhibitors in urology : Hypertension].
abstract: Tyrosine kinase inhibitors like sunitinib, sorafenib, pazopanib or axintinib are regarded the standard of care in the systemic therapy of metastatic renal cell carcinoma. However, the many side effects associated with this therapy pose challenges for the treating physician and the patient. This review offers an overview of the classification and the treatment of hypertension, which is one of the major side effects induced by all tyrosine kinase inhibitors, in order to improve treatment efficacy and patient compliance.
authors.affiliation: Urologische Universitätsklinik Erlangen, Universitätsklinikum Erlangen, Rathsberger Str. 57, 91054, Erlangen, Deutschland.
authors.forename: D
authors.initials: D
authors.lastname: Sikic
authors.affiliation: Medizinische Klinik 5, Universitätsklinikum Erlangen, Erlangen, Deutschland.
authors.forename: N
authors.initials: N
authors.lastname: Meidenbauer
authors.affiliation: Urologische Universitätsklinik Erlangen, Universitätsklinikum Erlangen, Rathsberger Str. 57, 91054, Erlangen, Deutschland.
authors.forename: V
authors.initials: V
authors.lastname: Lieb
authors.affiliation: Urologische Universitätsklinik Erlangen, Universitätsklinikum Erlangen, Rathsberger Str. 57, 91054, Erlangen, Deutschland. bastian.keck@uk-erlangen.de.
authors.forename: B
authors.initials: B
authors.lastname: Keck
mesh_terms: D000959:Antihypertensive Agents / Q000008:administration & dosage*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000556:secondary*; D019317:Evidence-Based Medicine; D006801:Humans; D006973:Hypertension / Q000139:chemically induced* / Q000517:prevention & control*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases
keywords: Axitinib; Cabozantinib; Pazopanib; Sorafenib; Sunitinib